• Where Quality is Paramount

  • Existing customer?


Pharmacy News

Latest News – PSNC Main site
Pharmaceutical Services Negotiating Committee

Class 2 Medicines recall: Ranitidine 75mg Tablets (Various Liveries)
Drug alert number: EL (19)A/37 Date issued: 21 November 2019 OTC Concepts Ltd, Relconchem Ltd and Noumed Life Sciences Ltd are recalling all unexpired batches of the products listed below from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential. OTC...

Have you signed up for priority access to utilities?
Community pharmacy contractors confirm each year that business continuity arrangements are in place via their information governance toolkit declarations (now known as the Data Security and Protection toolkit). You can now sign up for the Priority Services Register to boost your business continuity arrangements further. Inclusion on this register should mean your pharmacy has priority...

Contractor Notice: Further extension and amendment to SSP02 only
The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Fluoxetine capsules. The SSP for Fluoxetine 30mg capsules has been extended with a change to an alternative product (please check updated SSP02 protocol before dispensing), whilst the SSP for Fluoxetine 40mg capsules expired 20th November 2019....

Regulations Officer job opportunity at PSNC
PSNC is seeking a new recruit to support its legislative and regulatory affairs work. The appointee – Regulations Officer – will work closely with PSNC’s Director of Operations and Support, to provide guidance to pharmacy contractors and LPCs on the ‘terms of service’, market entry regulations, data protection issues and other legislative and regulatory matters affecting...

November 2019 Price Concessions – 1st update
Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack size Price Concession Alverine 60mg capsules 100 £9.25 Cefalexin 125mg/5ml oral suspension 100ml £1.95 Cefalexin 250mg/5ml oral suspension 100ml £2.25 Cyclizine 50mg/1ml solution for injection ampoules 5 £12.56 Hydroxyzine 25mg tablets 28 £1.02 Lamotrigine 100mg dispersible...

Campaigning for community pharmacy in the 2019 General Election
The National Pharmacy Association (NPA), Royal Pharmaceutical Society (RPS) and Pharmaceutical Services Negotiating Committee (PSNC) have created resources to help promote community pharmacy ahead of the General Election on 12th December. The upcoming election presents a great opportunity for the sector to be recognised as a valuable health and wellbeing asset, and a solution to...

Class 2 Medicines recall: Ranitidine Oral Solution 30mg/Ml (Creo Pharma Limited) and Ranitidine 150mg Tablets (Tillomed Laboratories Limited)
Drug alert number: EL (19)A/36 Date issued: 19 November 2019 Creo Pharma Limited and Tillomed Laboratories Limited are recalling all unexpired stock of the ranitidine Oral Solution 30mg/Ml and ranitidine 150mg Tablets listed below from pharmacies as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential....

EPS Phase 4 rollout begins with TPP SystmOne GP system
From today (18th November) EPS Phase 4 will begin rolling out to more GP practices using the TPP SystmOne GP system. All community pharmacy teams should therefore be aware that they may receive EPS Phase 4 tokens to process. Full rollout for TPP SystmOne GP system practices will take place in the coming weeks and...

Class 3 Medicines recall: Folic Acid tablets BP 5mg (Accord-UK Ltd)
Class 3 Medicines recall: Folic Acid tablets BP 5mg (Accord-UK Ltd) Drug alert number: EL (19)A/35 Date issued: 18 November 2019 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 3 medicines recall for: Folic Acid tablets BP 5mg (Accord-UK Ltd) Accord-UK Ltd has informed MHRA of an issue related to decommissioning...

CPCS Frequently Asked Questions
With the Community Pharmacist Consultation Service (CPCS) now bedding in, below you will find a selection of questions about the service which PSNC has been asked by LPCs and pharmacy teams over the last few weeks. View all our frequently asked questions on the CPCS Q. Will there be a training programme for CPCS? As...

Feeds from PSNC

Global Pharmaceutical News

PharmaTimes: PharmaTimes Website RSS
PharmaTimes - The latest news in healthcare and life sciences - PharmaTimes Website RSS

Smear test numbers rise 7.7%
New NHS statistics show an increase in uptake for the first time in five years.

BMS completes $74bn Celgene acquisition
Back in February, the purchase hit a significant obstacle after BMS’ largest institutional shareholder - Wellington Management - said it did not back the deal.

Sycona leads Azeria’s £32m financing round
The company was initially formed in 2017 off the back of research by Professor Jason Carroll, whose scientific insights have led to a new approach to target FOXA1 driven cancer.

EU approval for Keytruda in head and neck cancer
The MSD blockbuster has been approved as monotherapy or as part of a chemotherapy combination.

Myovant successful in Phase III prostate cancer trial
96.7% of men in the relugolix trial achieved sustained testosterone suppression to castrate levels.

More prescription ranitidine recalled from shelves
GSK’s formulation of the drug, Zantac, was recalled in the USA last month after the FDA found “unacceptable” levels of carcinogen in the medicine.

Bayer announces ‘Heart Mechanics’ workshop for schools
The four-hour workshop will educate students aged seven to 13 on heart health.

Stevenage Bioscience bags £1.2m cash injection
The money will go towards the development of the new “Spark Building”, which will provide interim lab and office accommodation whilst more permanent accommodation is developed nearby.

Entries well underway for the 2020 International Clinical Researcher of the Year
The 2020 competition has welcomed a strong start to entry numbers since launching in September.

PureTech schizophrenia drug shows mid-stage promise
The Phase II trial results are “impressive” and “encouraging”.

Health leaders urge government to ‘tackle huge pressures’
76% of health leaders said in a survey that supporting and growing the NHS workforce should be a critical priority, ranking it highest.

AZ’ Brilinta causes less bleeding as monotherapy
Co-administered with aspirin, Brilinta is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome.

Janssen pilots wearable technology in clinical trial
The Invokana trial will be completed virtually, with no in-person clinical visits required.

Lifescience Dynamics hires new chief business officer

Santhera appoints new chief executive officer


CPhl worldwide

Thame Laboratories will network among the industry’s key players

Every sector of the pharmaceutical market is represented under one roof, this year in Madrid. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.

Find out more: https://www.cphi.com/europe/

Have you got any questions about our products? We're here to help